Pfizer to acquire cancer drugmaker Seagen for $43bn in cash
American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, ... Read More
Seagen gets FDA accelerated approval for tucatinib, trastuzumab combo for colorectal cancer
American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa ... Read More
Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More
Takeda gets extended EC approval for ADCETRIS in sALCL
Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell ... Read More
PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been ... Read More
Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer
Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) ... Read More
EC approves ADCETRIS for treating CD30+ Stage IV Hodgkin lymphoma
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical's ADCETRIS (brentuximab vedotin) to include the treatment of previously untreated CD30+ Stage IV ... Read More
Seattle Genetics’ Adcetris receives FDA approval for peripheral T-cell lymphoma
Seattle Genetics' Adcetris, in combination with CHP chemotherapy, gains FDA approval for treating certain types of peripheral T-cell lymphoma. Seattle Genetics has announced that the ... Read More
Seattle Genetics to acquire Cascadian Therapeutics for $614m to bolster oncology portfolio
Seattle Genetics, a leader in oncology biotechnology, has announced the acquisition of Cascadian Therapeutics for approximately $614 million, a strategic move to enhance its portfolio ... Read More